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Background: Several candidate genes have been implicated in the etiology of
asthma, including the gene coding for the cystic fibrosis transmembrane con-
ductance regulator (CFTR). Mutations in the CFTR gene result in derangements of
mucociliary clearance. Homozygotes for CFTR mutations develop cystic fibrosis (CF),
a disorder characterized mainly by lung and pancreas disease.
Objective: To investigate whether there was an increased frequency of CFTR
mutations in asthma patients.
Methods: Seven hundred and three subjects aged 10–11 years from the environment
and childhood asthma (ECA) study were included in the present study. Possible
associations between asthma, reduced lung function, bronchial hyperresponsiveness
(BHR), and increased or decreased nitrogen oxide (NO) levels (based on structural
parental interview, spirometry, PD20 methacholine challenge test and exhaled NO
measurements), and the five most common CFTR mutations in Norway (DF508,
R117H, R117C, 4005+2T-C, 394delTT), the modulating polymorphisms IVS8(TG)mTn
and the IVS8-5T were investigated.
Results: No association were found between asthma, reduced lung function, BHR or
exhaled NO levels and CF heterozygosity. However, the IVS8(TG)11T7 haplotype was
associated with normal lung function.
Conclusions: Our results do not support the hypothesis that CFTR mutations or
polymorphisms play a role in the pathogenesis of asthma in children. However, theElsevier Ltd. All rights reserved.
ORAACLE (the Oslo Research Group of Asthma and Allergy in Childhood), which is part of the
11 87 65; fax: +47 22 11 86 63.
.uio.no (M.C. Munthe-Kaas).
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M.C. Munthe-Kaas et al.2122distribution of Tn(TG)m haplotypes differed between individuals with reduced lung
function and individuals with normal lung function.
& 2006 Elsevier Ltd. All rights reserved.Table 1 CFTR mutations in the Norwegian cystic
fibrosis patients [3].
CFTR mutation Alleles (%)
F508del 184 (62.2)
R117C 12 (4.1)
R117H 12
394delTT 11 (3.8)
4005+2T-C 11
G551D 6 (2.0)
3659delC 5 (1.7)
E60X 4 (1.4)
V232D 4
1525-2A-G 3 (1.0)
N1303K 3
G542X 2 (0.7)
E279X 2
R75X 2
S912X 2
E116X 1 (0.3)
L295Q 1
R347L 1
Q493X 1
I506L 1
I507del 1
R553X 1
G576A 1
621-1G-T 1
2183AA-G 1
S945L 1
R1162X 1
I1234V 1
3849+10 kbC-T 1
W1282X 1
Unknown 18 (6.5)
Total alleles 296 (100%)
Mutations detected with OLA31m kit—74%.
Bolded: five most frequent mutations—78%.
Detected with OLA 31m mutation kit.Introduction
Asthma is an inflammatory disease characterized by
recurrent symptoms due to airway obstruction.
Asthma prevalence has increased worldwide over
the last decades, and there is increasing evidence
of gene–environment interactions in disease devel-
opment.1 The Genetic Association Database
(http://geneticassociationdb.nih.gov) alone has
registered over 500 genetic association studies to
asthma.2 Among the candidate genes is the cystic
fibrosis transmembrane conductance regulator
(CFTR) gene on chromosome 7q32.
The CFTR gene codes for the cystic fibrosis (CF)
transmembrane conductance regulator. Mutations
in the CFTR alleles result in abnormal epithelial ion
and water transport and subsequent disturbances in
airway mucociliary clearance. More than 1400 CFTR
mutations are described conferring different de-
grees of CFTR protein malfunctions (http://
www.genet.sickkids.on.ca/cftr/). We have earlier
determined CFTR mutations in 148 Norwegian
patients with CF, and the most common mutations
are presented in Table 1.3 Mutations on both copies
of the CFTR results in classical CF, characterized by
progressive lung disease with severe chronic infec-
tions, bronchiectasies, pancreatic exocrine insuffi-
ciency, infertility in males, and elevated
concentrations of chloride in sweat.4 Other genetic
variations such as the thymidine tract polymorph-
ism (sometimes referred to as a mild mutation)5
and (TG)m repeats in intron 8 may also modify the
disease, as the IVS8-5T causes inefficient splicing of
intron 8 and thus reduces the amount of CFTR
transcripts. CF heterozygote carriers (in Norway
estimated to 3% of the population6) are generally
disease free, although it is speculated whether or
not heterozygosity predisposes for other inflamma-
tory conditions such as disseminated bronchiecta-
sies, bronchopulmonary aspergillosis, sinusitis and
asthma.7–9
Both CF and asthma are characterised by airway
inflammation and smooth muscle contraction due to
stimulation by host inflammatory mediators.10 Asth-
ma-like symptoms have been reported in 18% and
bronchial hyperresponsiveness (BHR) in 43% of CF
patients.11 However, exhaled nitrogen oxide (NO)
levels are increased in asthmatic airway inflamma-
tion,12,13 but decreased among CF patients.14Possible associations between CF genotypes and
asthma are unclear. Reports range from CFTR
heterozygosity conferring protection from asth-
ma,15 showing no association,7,16,17 to predisposing
for asthma.18–22 The variability in design, popula-
tions, statistical power, and clinical definitions of
asthma, make comparisons and interpretation
difficult. Thus, studies with sufficiently large
sample sizes and power with detailed clinical
phenotypes have been warranted.17
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CFTR gene mutations and asthma 2123We aimed to assess whether primarily asthma, or
variations in the asthma phenotype such as reduced
lung function, BHR or exhaled NO levels, were
associated with CFTR mutations and/or polymorph-
isms in a non CF population.Subjects and methods
Study design
In the prospective birth cohort study ‘‘The Environ-
ment and Childhood Asthma study’’ in Oslo (ECA
study) 3754 infants born during a period of 15
months from January 1, 1992 were recruited, as
described elsewhere.23 Briefly, inclusion criteria
were: birth-weight 42000 g, absence of illness
likely to impair respiration (severe respiratory,
cardiovascular, neuromuscular or metabolic dis-
ease) and no requirement for assisted ventilation
or oxygen therapy after 6 h of life. Exclusion
criteria were plans to move out of Oslo within 6
months and insufficient language skills among the
parents. Written informed consent was obtained
from parents of all subjects, and the study was
approved by the regional committee for medical
ethics and the Norwegian Data Directorate.
In a subgroup of 803 children lung function was
measured at birth.24 During the first 2 years, a
nested case–control study (ECA-1) was established
to perform detailed examinations of children with
recurrent (two or more) or persistent (44 weeks)
physician confirmed bronchial obstruction (rBO)
(n ¼ 306) and age-matched controls (n ¼ 306)
(the child born closest in time to the case without
lower respiratory illness).25 Two clinical investiga-
tions between 0 and 2 years were performed, with
at least one investigation in 562 children, and in
addition questionnaires including the child’s health
and diseases with specific and detailed questions
related to all types of infectious diseases, family
history of disease, socio-economic factors and
environmental exposure from birth to their second
birthday were completed by the parents every 6
months from birth through the child’s second
birthday.
A 10-year follow up, ‘‘The Environment and
Childhood Asthma study part 2 (ECA-2)’’ was
completed in 2004, including the children from
the nested case control study at 2 years as well as
all the children with lung function measurements at
birth.24 All traceable children were asked to attend
an examination (two visits) including a detailed
parental structured interview with core questions
from International Study of Asthma and Allergies inChildren (ISAAC) related to airways symptoms of
the child and detailed questions regarding environ-
mental exposure, life-style and diseases. In addi-
tion, the examination performed at least 4 weeks
after any suspicion of respiratory tract infection
included blood tests (DNA), skin prick tests for
allergic senitization, spirometry, PD20 methacho-
line challenge test, exhaled nitric oxide, urine
sampling and clinical examinations on day one, and
an exercise test by treadmill running within a
week. The present study reports results from the
structured interview, spirometry, PD20 methacho-
line challenge test, and exhaled nitric oxide.Subjects
The children included in the present study were the
first 703 of the included 1019 children who
attended the 10-year follow-up in ECA-2. This was
not a random selection of children from the child
birth cohort, since those with lung function
measurements at birth and those included in the
2-year case–control follow up study were prior-
itized, and thus children with asthma were over-
represented (see Table 2). Technical difficulties
precluded DNA analysis in five subjects. Of the
remaining 698 included subjects, one subject
had insufficient information to establish an
asthma diagnosis.24 The related phenotypes were
ascertained in the following number of subjects:
FEV1 measurements in 688 subjects, PD20 metha-
choline challenge test for BHR in 682 subjects, and
exhaled nitric oxide measurements in 431 subjects
(Table 2).Methods
Forced expiratory flow volume loops were mea-
sured according to European standard26 (reference
values of Zapl et al.27) on a SensorMedics Vmax 20c
(SensorMedics Diagnostics, Yorba Linda, CA, USA)
on four occasions; prior to metacholine and
exercise challenge tests and after salbutamol given
at the end of challenge tests, respectively (on
separate days), and at least 4 weeks after any
suspected respiratory tract infection. The following
medication was not taken for the given time prior
to investigation; short acting bronchodilator for
12 h, long acting bronchodilator/leukotriene recep-
tor antagonist for 72 h, long-acting antihistamine
for 7 days, systemic steroids for a month. The
reported values were the best baseline values
obtained before either of the challenge tests.24
BHR was assessed with a dosimetric methacho-
line challenge test according to international
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Table 2 Clinical baseline characteristics of study population.
No. of
subjects
analyzed
All children
(n ¼ 698)
Children
with asthma
(n ¼ 236)
Children
without
asthma
(n ¼ 461)
P-value
Gender (male) n/% 698 377 (54%) 144 (61%) 233 (51%) 0.01
Mean lung function 7SD (FEV1(L)) 688 2.1070.31 2.0370.29 2.1370.31 o0.01
Reduced lung function n/%
(FEV1% pred o80%)
688 21 (3%) 9 (4%) 12 (3%) 0.37
BHR n/% (PD20p8 mmol) 682 229 (34%) 106 (46%) 123 (27%) o0.01
Mean FeNO level 7SD (ppb) 431 8.5277,32 10.6678,87 7.4076.09 o0.01
Increased FeNO levels n/%
FeNO415.6 ppb
431 45 (11%) 31 (21%) 14 (5%) o0.01
Low FeNO levels n/% FeNOo2.5 ppb 431 15 (4%) 1 (1%) 14 (5%) 0.02
Parental asthma n/% 679 129 (19%) 68 (29%) 61 (13%) o0.01
Allergy (SPT pos) # n/% 689 193 (28%) 85 (36%) 108 (24%) o0.01
Baseline characteristics of the study population given as total numbers as well as among children with and without asthma.
The P-value refers to comparison of the groups of children with and without asthma. Information was lacking for asthma
diagnosis in one child. BHR: refers to positive bronchial hyper responsiveness FeNO: exhaled nitric oxide.
Parental asthma includes at least one parent reporting asthma.
# Allergy was defined as at least one positive skin prick test (SPT).
M.C. Munthe-Kaas et al.2124guidelines.28 In short, methacholine was delivered
in successive increasing doses ranging from
0.05 mmol up to a cumulative dose of 22.4 mmol.
The dose (mmol) at which a fall in FEV1 of 20%
(PD20) was identified by linear interpolation on the
dose response curve.
Exhaled NO levels were measured with Eco
Medics CLD 88 analyzer (ECO MEDICS AG, Duernten,
Switzerland) using single exhalation techniques
with 50ml/min flow in accordance to ERS/ATS
guidelines.29 The mean value of three expira-
tory NO concentrations was calculated from each
subject.Genotyping
DNA was isolated from peripheral blood by the use
of a magnetic beads based method on the instru-
ment MagnaPure LC (Roche). The CFTR mutations
DF508, R117H, 4005+2T-C, 394delTT, IVS8
Tn(TG)m were analyzed by different PCR-based
methods, as described in details below.
PCR and fragment analysis for the 394delTT and
delF508 were performed in a multiplex reaction
with the following primers:
394F (forward) 50-FAM-GCAGAGAATGGGATAGA-
GAGC-, 394R (reverse) 50-ATTCACCAGATTTCGTA-
GTC- and F508F (forward) 50-HEX-GCCTGGCACCAT-
TAAAGAA—and F508R (reverse) 50-AGTTGGCATGC-
TTTGATGAC-. Fragment representing a normal 394-
allele was199 bp while a normal F508-allele was
84 bp. The deletion specific alleles were 197 and81 bp, respectively. Fragment sizes were detected
on capillary electrophoresis on ABI310 (Applied
Biosystems).
The variable number of T-bases and TG-repeats
in intron 8 were analyzed by multiplex PCR and
fragment analysis with a common forward primer
50-TAATGG ATCATGGGCCATGT- and differently la-
belled reverse primers specific for the numbers of
T’s: 5TR 50-FAM-CCCCAAATCCCTGTTAAAAAC-, 7TR
50-HEX-CCCCAA ATCCCTGTTAAAAAA AC- and 9TR 50-
NED-CCCCAAATCCCTGTT AAAAAAAAA C—producing
amplicons of approximately 136 bp, depending on
the number of TG-repeats. The fragment lengths
were determined by capillary electrophoresis on
ABI310. In order to correlate the IVS8 Tn(TG)m
haplotype to the fragment lengths, a couple of
samples were sequenced and used as standards.30
R117C was analyzed by PCR with the forward
primer 50-M13-TTCACATATGGTATGACCCTC and re-
verse primer 50- TTGTACCAGCTCACTACCTA fol-
lowed by restriction digestion by BsmI and
visualized on agarose gel. The fragment sizes from
normal samples were 330 and 126 bp, while
heterozygote samples got additional bands of 228
and 102 bp.31
R117H was analyzed in two separate PCR’s with a
common forward primer C: 50 TCACATATGGTAT-
GACCCTC, and with normal specific arms reverse
primer in one tube 50-CTTATGCCTAGATAAATCGCGA-
TAGAAC and mutated specific arms reverse primer
50-CTTATGCCTAGATAAATCGCGATAGACT in the other
tube. A R117H heterozygote sample would produce
a 237 bp long fragment in both reactions.
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forward primer 50-GGTCAGGATTGAAAGTGTGCA
and the reverse primer 50- CTATGAGAAAACTG-
CACTGGA, followed by restriction digestion by
Hph I and visualized on agarose gel. The digested
normal PCR product yielded fragments of 266, 137
and70 bp, while the mutated PCR product with a
loss of restriction site yielded fragments of 403 and
70 bp. The method is described earlier by Boman
et al. CF consortium Newsletter #69.
Assay specific heterozygote control samples were
included in every PCR run. Further details will be
given upon request.
Outcomes
Asthma was defined by fulfilling at least two of the
following three criteria:241. Dyspnoea, chest tightness and/or wheezing ever.
2. A physician’s diagnosis of asthma.
3. Use of asthma medication (b-2 agonist, sodium
cromoglycate, corticosteroids, leukotriene an-
tagonists and/or aminophylline).
The secondary outcomes were defined as:
Lung function: Reduced lung function was
defined as FEV1% predicted below 80%.27
BHR: Individuals with PD20 value of p8.0 mmol
were defined as exhibiting BHR.
Increased or decreased exhaled NO levels:
Healthy subjects in the present study (no asthma)
were used to establish a normal reference
interval (mean 7.34ppb, standard deviation
6.12). Upper limit was set to the 95th percentile
and lower limit to the 5th percentile, 15.6 and
2.5 ppb, respectively. Individuals with FeNO va-
lues above 15.6 ppb were defined as having
increased FeNO, and those with FeNO values
below 2.5 ppb as having low FeNO.
Genotypic outcomes were defined into following
groups:
CF heterozygotes: those subjects that were
heterozygote for one of the five CFTR mutations.
CF heterozygotes including the IVS8-5T poly-
morphism: those subjects that were heterozy-
gote for either one of the five CFTR mutations or
the IVS8-5T polymorphism, since this polymorph-
ism, in some studies, is referred to as a mild
mutation.
Tn(TG)m haplotypes: subjects were divided
into haplotype groups depending on number ofTG repeats (10, 11 or 12) and T repeats (5T, 7T
or 9T).
Statistical analysis
The study was designed to detect a difference of 6%
or more in CFTR carrier status between asthmatic
and non-asthmatic subjects, a difference based on
frequency of CFTR carrier status in the general
Norwegian population6 and CFTR carrier frequen-
cies among asthmatics in Denmark.20 Using Sample
Power 2000 (http://www.spss.com) (comparison of
proportions), proportions 0.03 (carrier status in
general population) versus 0.09 (carrier status
among asthmatics), and a desired 80% power with
significance level P at 0.05, at least 200 asthmatics
and 400 controls were required. P-values below
0.05 were considered statistically significant.
Possible associations between categorical vari-
ables were analyzed using Pearson’s w2 analysis for
dichotomous outcomes in Statistical Package for
Social Sciences (SPSS) version 11.Results
The mean age of the subjects included in the study
was 10.4 years (SD ¼ 0.6). Fifty-four percent were
boys (Table 2). In the study group as a whole, 34%
had asthma, 3% had FEV1% predicted below 80%,
34% exhibited BHR, 11% had increased FeNO levels
and 4% had low FeNO levels. For detailed descrip-
tion of how these phenotypes varied between
the asthma group and the non asthma group, see
Table 2.
Five percent of the study population were CF
heterozygotes and 3.7% carried the IVS8-5T
polymorphism. There were no associations be-
tween asthma, reduced lung function, BHR, or
FeNO levels and CF heterozygosity, both when
including and excluding the IVS8-5T polymorphism
(Fig. 1a and b). However, a significant association
between normal lung function and the IVS8(TG)11
T7 haplotype was found by haplotype analysis
(Table 3).
Among children with asthma only, there were no
associations between reduced lung function, BHR
and FeNO levels and CFTR mutations or
IVS8(TG)mTn haplotypes.Discussion
The present study found no significant association
between asthma, reduced lung function, BHR or
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Figure 1 (a) Percentage of CF heterozygotes in asthma, reduced lung function, bronchial hyperresponsiveness (BHR)
and exhaled nitric oxide (FeNO) levels. Bars represent percentage of CF heterozygotes in groups with or without
asthma, reduced lung function, BHR, increased and decreased FeNO. The P-values for each group are indicated along
the X-axis. (b) Percentage of CF heterozygotes and IVS8-5T polymorphism in asthma, reduced lung function, bronchial
hyperresponsiveness (BHR) and exhaled nitric oxide (FeNO) levels. Bars represent percentage of combined CF
heterozygotes and the IVS8-5T polymorphism in groups with or without asthma, reduced lung function, BHR, increased
and decreased FeNO. The X-axis represents P-values for each group separately.
Table 3 Reduced lung function and the Tn(TG)m haplotypes.

Tn(TG)m Reduced lung function no. of
alleles (expected no.)
Normal lung function no. of
alleles (expected no.)
T5(TG)10 0 (0) 1 (1)
T5(TG)11 0 (1) 22 (21)
T5(TG)12 1 (0) 2 (3)
T7(TG)10 10 (10) 309 (309)
T7(TG)11 17 (23) 733 (727)
T7(TG)12 7 (4) 105 (108)
T9(TG)10 6 (3) 101(104)
T9(TG)11 1 (1) 45 (45)
Total # alleles 42 1318
Distribution of Tn(TG)m haplotypes in the subjects with reduced lung function (FEV1% predicted below 80%) versus normal lung
function. Significance of P ¼ 0:01 for the w2 test as a whole, and the haplotype distribution that differs from the expected is
bolded.
Allele count.
M.C. Munthe-Kaas et al.2126FeNO levels and CF heterozygosity (both when
including or excluding the IVS8-5T polymorphism)
or the modulating polymorphism (IVS8(TG)mTn).
However, the IVS8(TG)11T7 haplotype alone was
associated with normal lung function.The lack of significant association between CF
heterozygosity and asthma found in the present
study is supported by studies from the UK,16
France17 and Italy.32 Furthermore, a linkage study
from Iceland failed to show evidence of linkage
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CFTR gene mutations and asthma 2127between chromosome 7q32 and asthma.33 This is in
contrast to studies from Denmark,18–20 Greece21
and Spain22 that reported positive association
between asthma and CF heterozygosity and one
study from the US15 that concludes that CF
heterozygosity confers protection against asthma.
To our knowledge, the relationship between
IVS8(TG)mTn haplotypes and lung function has not
previously been explored, although a recent study
from Denmark found no association between the
IVS8-5T polymorphism and annual decline in FEV1 or
asthma.34 The IVS8(TG)11T7 was the most common
haplotype in our population, similar to findings in a
Greek study by Tzetis et al.21 The higher frequency
of the IVS8(TG)11T7 haplotype among our subjects
with normal versus reduced lung function is in line
with the findings in Tzetis’ study, where they detect
a higher frequency of the IVS8(TG)11T7 haplotype
among healthy controls versus asthmatic pa-
tients.21 The IVS8(TG)12/13T5 haplotype has been
associated to congenital bilateral absence of vas
deferens (CBAVD)35 and IVS8(TG)11/12/13T5 to pul-
monary diseases.21 In the present study, only 21
subjects had reduced lung function (estimated by
Zapletal’s reference values), leaving insufficient
power to determine whether this was associated
with similar haplotypes. However, since the
IVS8(TG)11T7 haplotype possibly protected against
reduced lung function, one might speculate
whether these modulating polymorphisms exert
an effect on lung physiology in general and not on
lung function specifically in subjects with asthma.
The strength of the present study is the detailed
and well described population that has been
followed for 10 years with a design especially
suited for investigating asthma and asthma pheno-
types. Thus, the discrepancies concerning the
asthma diagnosis are minimized. Furthermore, we
anticipated that if CFTR mutations are clinically
relevant for asthma, they should be found among
the most common mutations in the population
studied. Thus, we analyzed the five most common
CFTR mutations, covering 78% of known CF muta-
tions in our native population. Finally, the present
study represents, to our knowledge, the largest
case–control population with sufficient power
especially designed to look at clinically ascertained
asthma among the CFTR—asthma studies, and the
results from the present study are supported by the
comparable French EGEA study.17
In addition to asthma, reduced lung function,
BHR and increased FeNO levels were analyzed
separately. Although power estimates ascertained
sufficient study power for asthma only, the lack of
associations between CFTR mutations and lung
function, BHR and increased FeNO levels supportthe main conclusion of no association between
asthma and CFTR genotypes. In fact, as can be seen
in Fig. 1a and b, the percentage of CF hetero-
zygosity (both including and not including the IVS8-
5T polymorphism) was higher in subjects without
reduced lung function, BHR or increased FeNO
levels than in those with the clinical traits.
A limitation of the present study was that the
entire CFTR gene was not screened to fully exclude
association. Secondly, the subject population was
recruited from a healthy birth cohort and included
few subjects with low lung function (only 21
subjects with FEV1% predicted below 80%), and
the Bonferroni corrected P-value of significance for
the association between IVS8(TG)11T7 haplotype
and reduced lung function is a borderline 0.04
(original P-value multiplied by the four phenotypes
analyzed). Thus, the possible significance of
IVS8(TG)mTn haplotypes for lung remains to be
ascertained.
In conclusion, CFTR heterozygosity was not
associated with asthma, reduced lung function,
BHR or exhaled NO levels in children, whereas the
IVS8(TG)11T7 haplotype was associated with normal
lung function. We suggest that future efforts to
understand the role of CFTR genotypes should focus
on possible associations with lung function rather
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